Skip to content

Neuroprotective Effects of Statins in patients with acute ischemic stroke

Neuroprotective Effects of Statins in patients with acute ischemic stroke

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15006734
Enrollment
Unknown
Registered
2015-07-10
Start date
2015-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Interventions

low-statin:atorvastatin 10mg
large-statin:atorvastatin 80mg

Sponsors

Department of neurology of Hospital of Shenyang military area command of Chinese PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. The patients with clear consciousness should sign informed consent,or the legal representative of the patients should sign informed consent; 2. The patients should be diagnosed as acute ischemic stroke within 48 hours of onset.Diagnostic criteria should meet the diagnosis standard revised in the Fourth National Academic Conference on cerebrovascular disease; 3. The age of the patients regardless of gender should be between 18-80; 4. Neurological deficits include NIHSS scores of 6-20; 5. There is no bleeding in brain CT; 6. The patients should have the first stroke attack,or the patients should have the second stroke attack with no sequel of the first stroke attack, or the patients should have the second stroke attack with clear NIHSS scores.

Exclusion criteria

Exclusion criteria: 1. Patients with liver diseases (glutamic pyruciv transaminase or aspartate aminotransferase is higher than the normal value of 1~1.5 times), kidney diseases (urea or creatinine is greater than the normal range above 10%), increase in muscle enzymogram above 10%; 2. Patients having a history of allergy to this class of drugs; 3. Patients who participated in other clinical trials within 3 months; 4. Patients previously taking statins in 3 months.

Design outcomes

Primary

MeasureTime frame
NIHSS scores;mRS;Baethel Index;Stroke recurrence;cardiovascular event;

Secondary

MeasureTime frame
HAMA;HRSD;MMSE;MoCA;BAI and PWV;color Doppler ultrasonography;

Countries

China

Contacts

Public ContactChen Huisheng
chszh@aliyun.com+86 13352452086

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026